Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "Proximal tubule" patented technology

The proximal tubule is the segment of the nephron in kidneys which begins from the renal pole of the Bowman's capsule to the beginning of loop of Henle. It can be further classified into the proximal convoluted tubule (PCT) and the proximal straight tubule (PST).

Method for the early detection of renal injury

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1

Method for the early detection of renal injury

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:DEVARAJAN PRASAD +1

A method and kit for detecting the early onset of renal tubular cell injury

An early-onset method and kit for detecting renal tubular cell injury, using NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and thus readily detected in urine following tubular cell injury. NGAL protein expression was mainly detected in the proximal tubule cells, which resembled a secreted protein with a punctate distribution in the cytoplasm. Apparent NGAL in urine correlates with the amount and duration of renal ischemia and nephrotoxicemia and is a diagnostic feature of tubular cell injury and renal failure. NGAL detection is also a useful marker for monitoring nephrotoxic side effects of drugs or other therapeutic agents.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1

Double antibody latex enhanced retinol binding protein detection kit

The invention relates to a double antibody latex enhanced retinol binding protein detection kit. More specifically, the invention discloses a double antibody coating latex enhanced immunoturbidimetry kit for detecting retinol binding protein. The kit contains a reagent 1, a reagent 2 and a calibrator. Paring monoclonal antibody A and B are respectively coated on latex particles. Coated antibody is bonded with RBP to be detected, and a plurality of bonders are aggregated together to form detectable turbidity change. The detection kit provided by the invention has high sensitivity, can be used to detect urine samples and serum samples and can be used as nutritive index to detect RBP in serum. Simultaneously, through the detection of RBP in urine, the kit is sensitive to the damage degree of renal proximal tubule.
Owner:BEIJING STRONG BIOTECH INC

Method and kit for detecting the early onset of renal tubular cell injury

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Use of cilastatin to reduce nephrotatoxicity of various compounds

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.
Owner:FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON

Method for the early detection of renal injury

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Bioartificial kidneys

The present invention generally relates to improved bioartificial kidneys (BAKs), and in certain embodiments to improved bioartificial kidneys that are portable and / or wearable by a user. In some embodiments, the BAKs may comprise an ultrafiltration unit and a reabsorption unit. The reabsorption unit may contain a reabsorption membrane having a layer of renal proximal tubule cells disposed thereon, where the renal proximal tubule cells selectively allow solutes to pass through the reabsorption membrane. In some embodiments, at least the reabsorption unit may be configured as a substantially flat-plate filtration device, which can impart advantageous properties such as improved maintenance of the renal proximal tubule cell layer, more facile monitoring of the renal proximal tubule cell layer as well as enhanced profile for wearability.
Owner:AGENCY FOR SCI TECH & RES

Method and kit for detecting the early onset of renal tubular cell injury

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Reversible immortalization of human renal proximal tubular epithelial cells

The present provides reversibly immortalized RPTECs and methods for making and utilizing these cells. Specifically, the present invention provides a method of reversibly immortalizing RPTECs by introducing a first vector containing a human telomerase catalytic subunit (hTERT) gene flanked by loxP sites and a second vector containing an SV40 T antigen (Tag) gene flanked by loxP sites. Immortalization can be reversed by introduction of a third vector containing a Cre recombinase or Cre variant gene. The reversibly immortalized RPTECs generated by this method may be used for a variety of applications, including screening of test agents for the ability to modulate renal toxicity or incorporation into devices designed to mimic the activity of the renal proximal tubules.
Owner:CITY OF HOPE

Double coating procedure for the membranes of bioartificial kidneys

The present invention generally relates to modified substrates such as membranes for use in bioartificial organs, such as bioartificial kidneys, and other applications. Certain aspects are generally directed to a membrane or other substrate modified to facilitate the attachment of cells. In one set of embodiments, the substrate or membrane may be at least partially coated with an adhesive such as 3,4-dihydroxy-L-phenylalanine (DOPA), poly(dopamine), or other adhesive comprising a molecule having a catechol moiety, for example on one side of the membrane or substrate. On at least a portion of the adhesive coated portion of the substrate, a protein may be coated, such as an extracellular matrix protein (for example, a collagen), to which cells such as primary human renal proximal tubule cells may be adhered. Surprisingly, such a dual coating may be used to promote the attachment of such cells to a membrane or other substrate that otherwise may not promote cell adhesion. In certain embodiments, the coating may also facilitate or promote not only cell adhesion, but also cell proliferation and / or differentiation. Such membranes or other substrates may be useful, for example, in bioartificial organs such as bioartificial kidneys, hemodialysis cartridges, bioimplants, biosensors, bioreactors, etc. In certain embodiments, cells may be attached to a membrane or other substrate on only one side, while the other side may be kept free of attached cells.
Owner:AGENCY FOR SCI TECH & RES

Bioreactor unit for use in bioartificial kidney device

ActiveUS20150076066A1Increased platelet adhesionIncreased membrane cloggingBioreactor/fermenter combinationsSemi-permeable membranesFiberHollow fibre membrane
There is provided a bioreactor device having cells, including human primary proximal tubule cells (HPTCs) or HPTC-like cells on the exterior surface of hollow fiber membranes included within the device. Also provided are bioartificial kidney devices incorporate the bioreactor device and methods of using such devices.
Owner:AGENCY FOR SCI TECH & RES

Use of cilastatin to reduce nephrotatoxicity of various compounds

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.
Owner:FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON

Method and system for diagnosing and treating preeclampsia

Described herein are methods, systems and kits of the diagnosis of preeclampsia and HELLP syndrome, as well as the selection of a preeclampsia or HELLP syndrome treatment. These are based, at least in part, on the finding that proximal tubule injury, as measured by urinary KIM-1, is increased in severe preeclampsia and correlates with complement activation. The detection of complement proteins correlate with kidney injury in severe preeclampsia and / or HELLP syndrome and terminal complement blockage is a therapeutic approach taken as described in various embodiments of the present invention.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Tubular fiber membrane with nanoporous skin

A wet spinning process for forming a tubular fiber membrane is provided. The tubular fiber membrane has a nanoporous skin layer and a microporous lumen layer. The skin layer defines an outer surface of the fiber membrane and the lumen layer defines a lumen surface of the fiber membrane. The pores in the skin layer may have an average pore size of less than about 7 nm, and pores in the lumen layer may have an average pore size of from about 0.5 to about 3 μm. The fiber membranes may be used in artificial renal proximal tubules, artificial kidneys, bioreactors, or fiber cartridges.
Owner:AGENCY FOR SCI TECH & RES

Tubular fiber membrane with nanoporous skin

A wet spinning process for forming a tubular fiber membrane is provided. The tubular fiber membrane has a nanoporous skin layer and a microporous lumen layer. The skin layer defines an outer surface of the fiber membrane and the lumen layer defines a lumen surface of the fiber membrane. The pores in the skin layer may have an average pore size of less than about 7 nm, and pores in the lumen layer may have an average pore size of from about 0.5 to about 3 μm. The fiber membranes may be used in artificial renal proximal tubules, artificial kidneys, bioreactors, or fiber cartridges.
Owner:AGENCY FOR SCI TECH & RES

Glufosfamide combination therapies for cancer

The invention provides compositions and methods for treating cancer with glufosfamide in combination with an inhibitor of sodium-glucose transporter type 2 (SGLT2) to block the uptake of glucose in the proximal tubules of the kidneys to decrease renal toxicity. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
Owner:ELEISON PHARMA

Expression of the cysteine protease legumain in vascular and inflammatory diseases

The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and / or ZB-1 activity, expression, and / or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and / or preventing vascular disorders / diseases and inflammatory disorders / diseases.
Owner:WYETH LLC

Microfluidic proximal tubule kidney-on-chip

The present invention relates to microfluidic fluidic devices, methods and systems as microfluidic kidney on-chips, e.g. human Proximal Tubule-Kidney-Chip, Glomerulus (Kidney)-Chip, Collecting Duct (Kidney)-Chip. Devices, methods and systems are described for drug testing including drug transport and renal clearance. Further, such devices, methods and systems are used for determining drug-drug interactions and their effect upon renal transporter functions. Importantly, they may be used for pre-clinical and clinical drug development for treating kidney diseases and for personalized medicine.
Owner:EMULATE INC

Double coating procedure for the membranes of bioartificial kidneys

The present invention generally relates to modified substrates such as membranes for use in bioartificial organs, such as bioartificial kidneys, and other applications. Certain aspects are generally directed to a membrane or other substrate modified to facilitate the attachment of cells. In one set of embodiments, the substrate or membrane may be at least partially coated with an adhesive such as 3,4-dihydroxy-L-phenylalanine (DOPA), poly(dopamine), or other adhesive comprising a molecule having a catechol moiety, for example on one side of the membrane or substrate. On at least a portion of the adhesive coated portion of the substrate, a protein may be coated, such as an extracellular matrix protein (for example, a collagen), to which cells such as primary human renal proximal tubule cells may be adhered. Surprisingly, such a dual coating may be used to promote the attachment of such cells to a membrane or other substrate that otherwise may not promote cell adhesion. In certain embodiments, the coating may also facilitate or promote not only cell adhesion, but also cell proliferation and / or differentiation. Such membranes or other substrates may be useful, for example, in bioartificial organs such as bioartificial kidneys, hemodialysis cartridges, bioimplants, biosensors, bioreactors, etc. In certain embodiments, cells may be attached to a membrane or other substrate on only one side, while the other side may be kept free of attached cells.
Owner:AGENCY FOR SCI TECH & RES

Delivery of bmp-7 and methods of use thereof

The present invention generally relates to delivery of BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist and methods of use thereof. In some embodiments, methods and devices are provided for delivery of BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist to a patient. In some cases, the BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist may be released in controlled fashion from a device in fluid communication with a patient. In some embodiments, the BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist may be expressed by cells within a device. In other embodiments, methods are provided for improving the function of devices containing renal proximal tubule cells. For example, in some embodiments, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist may be used to inhibit disruption of cell layers comprising renal proximal tubule cells. In another embodiment, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist may be used to inhibit trans- and de-differentiation of renal proximal tubule cells. In another embodiment, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and / or a BMP-7 agonist may be used to improve renal proximal tubule cell functions.
Owner:AGENCY FOR SCI TECH & RES

Mesoscale nanoparticles for selective targeting to the kidney and methods of their therapeutic use

A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters

InactiveUS20130130223A1Genetically modified cellsArtificial cell constructsMicroorganismPharmacology toxicology
The invention relates to the field of biology and medicine. In particular, the invention relates to the field of pharmaceutical research and drug development, and especially to means for physiological, pharmacological and toxicological research. More in particular, the invention provides renal cell lines with proximal tubular characteristics including multiple influx and efflux transporters. These cell lines are termed ciPTEC. Four representative examples have been deposited at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ or German Collection of Microorganisms and Cell Cultures) at Inhoffenstrasse 7 B, 38124 Braun-schweig, Germany under accession number DSM ACC3019, DSM AC-C3020, DSM ACC3021 and DSM ACC3022.
Owner:STICHTING KATHOLIEKE UNIV

15-methylene-14-deoxy-11,12-dehydro-andrographolide derivative and drug application thereof

The invention belongs to the technical field of medicine, and relates to a 15-methylene-14-deoxy-11,12-dehydro-andrographolide derivative. Experiments prove that the compounds obviously inhibit the migration and activation of hepatic stellate cells, obviously inhibit the mesenchymal transition of TGF-beta 1-induced human alveolar type II epithelial cells A549, obviously inhibit the mesenchymal transition of human renal cortex proximal convoluted tubule epithelial cells HK-2, and obviously inhibit the migration of angiotensin II (Ang II)-induced primary human cardiac fibroblasts HCFB. The compound is taken as an active ingredient for preparing anti-fibrosis drugs, has high efficiency and low toxicity, provides a new drug route for the treatment and prevention of fibrosis-related diseases, and thus the selectable range of clinical drugs is expanded, so that the derivative has a good application and development prospect.
Owner:ZHENGZHOU UNIV

Application of 14-deoxy-11, 12-dehydrogenation-7, 8-ene-andrographolide and 15-subunit substituted derivative

The invention belongs to the technical field of medicines, and discloses an application of an andrographolide derivative in the preparation of medicaments for preventing and treating various fibrosis.The invention relates to an application of 14-deoxy-11, 12-dehydrogenation-7, 8-ene-andrographolide and a 15-subunit substituted derivative. Experiments prove that the compound obviously inhibits themigration and activation of hepatic stellate cells; significantly inhibits TGF-beta1 induced mesenchymal transformation of human alveolar type II epithelial cells A549; significantly inhibits TGFbeta1 induced HK-2 mesenchymal transformation of human renal cortical proximal tubular epithelial cells; inhibits the migration of HCFB in primary human cardiac fibroblasts induced by angiotensin II (AngII). In a model of common bile duct ligation in mice, a model of pulmonary fibrosis induced by silica in mice and a model of unilateral ureteral ligation in mice, the compound shows good anti-fibrosisactivity in vivo. The compound is used as an active ingredient for preparing the anti-fibrosis medicament, has high efficiency and low toxicity, and has a good prospect of developing various anti-fibrosis medicaments.
Owner:ZHENGZHOU UNIV

Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases

The invention comprises novel compositions, systems, and methods for the analysis of biological samples, such as urine samples, in order to diagnose and treat kidney disease, including without limitation, glomerulonephritis, nephrotic syndrome, diabetes, lupus, hypertension, acute tubular necrosis, obstructive disorders of the urinary tract, renal cancers and other diseases or syndromes. In preferred embodiments, the invention comprises the identification of particular genes expressed only in cells of particular clinical or scientific interest in the urinary tract, such as podocytes or proximal tubule cells. Thus, the invention enables non-invasive, rapid and accurate analysis of kidney and urinary tract status and function in many medical diseases and disorders.
Owner:RGT UNIV OF MICHIGAN

Bioartificial proximal tubule systems and methods of use

This application invention discloses bioartificial proximal tubule device, constructed by preparing a decellularized biological matrix, seeding the biological matrix with mammalian kidney-derived cells and optionally mammalian endothelial cells. The device may then be cultured statically or matured using bioreactor culture to allow differentiation of the kidney cells into functioning proximal tubule cells. The device is capable of carrying out proximal tubule functions. The application also describes various methods of making the proximal tubule devices. The application also further describes methods of use of bioartificial proximal tubule devices for e.g. in vitro studies of tubule cell transport, toxicity effects of various compounds or pharmaceutical compound screening.
Owner:DEPUY SYNTHES PROD INC

Double Antibody Latex Enhanced Retinol Binding Protein Detection Kit

The invention relates to a double antibody latex enhanced retinol binding protein detection kit. More specifically, the invention discloses a double antibody coating latex enhanced immunoturbidimetry kit for detecting retinol binding protein. The kit contains a reagent 1, a reagent 2 and a calibrator. Paring monoclonal antibody A and B are respectively coated on latex particles. Coated antibody is bonded with RBP to be detected, and a plurality of bonders are aggregated together to form detectable turbidity change. The detection kit provided by the invention has high sensitivity, can be used to detect urine samples and serum samples and can be used as nutritive index to detect RBP in serum. Simultaneously, through the detection of RBP in urine, the kit is sensitive to the damage degree of renal proximal tubule.
Owner:BEIJING STRONG BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products